MedTrace Logo

Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers

NCT01604122 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2023-04-06

Study results available
· View outcomes & findings →

Summary

This study is an online (web-based) or paper-based survey for patients with transthyretin familial amyloidosis polyneuropathy (TTR-FAP) and caregivers. The results will be used to describe the emotional, physical, and financial impact of having TTR-FAP or caring for someone who has the disease.

Conditions

  • Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP)
  • Transthyretin Cardiomyopathy (TTR-CM)
  • Familial Amyloid Cardiomyopathy
  • Senile Systemic Amyloidosis (SSA)

Interventions

OTHER

No drug

No drug.

OTHER

No drug

No drug.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-18
Primary Completion
2015-07-27
Completion
2016-07-18

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01604122 on ClinicalTrials.gov